Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Robotic bronchoscopy: potential in diagnosing and treating lung cancer
Duke, Jennifer D. , Reisenauer, Janani

Mayo Clinic

Expert Review of Respiratory Medicine | March 20, 2023 | Volume: 17 | Issue: 3 | Pages: 213-221

10.1080/17476348.2023.2192929 | PMID 36939545 Get It

Migraine Patient Care Model Preferences in a Community Practice
Stern, Jennifer I. , Ebbert, Jon O. , Young, Nathan P. , Young, Nathan P , Vierkant, Robert A.

Mayo Clinic

Neurology Clinical Practice | March 19, 2023 | Volume: 13 | Issue: 2 | Pages: No page available

10.1212/cpj.0000000000200131 | PMID 37064592 Get It

A Community Paramedic Clinic at a Day Center for Adults Experiencing Homelessness
Ridgeway, Jennifer L. , Finnie, Dawn M., Wiepert, Liana M , Glasgow, Amy E. , Torres, Andrew J., Juntunen, Michael B. , Liedl, Chad P., Ridgeway, Jennifer L , Gerdes, Erin O. Wissler , Zhu, Xuan , Torres, Andrew J., Smith, Olivia A., McCoy, Rozalina G.

Mayo Clinic

NEJM Catalyst | March 15, 2023 | Volume: 4 | Issue: 4 | Pages: No page available

10.1056/cat.22.0300 Get It

NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
Karrison, Theodore , Pisansky, Thomas M. , Posadas, Edwin M. , Hall, William A. , Rodgers, Joseph P., Feng, Felix Y. , Koontz, Bridget F. , Ballas, Leslie , Berlin, Alejandro , Tran, Phuoc T , O'Daniel, Jennifer C , Hope, Thomas A.

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: TPS283-TPS283

10.1200/jco.2023.41.6_suppl.tps283 Get It

TPS283 Background: There is no clear standard of care for biochemically recurrent prostate cancer (PCa) with positron emission tomography (PET)-detected oligometastases and normal conventional imaging (CIM). Phase II trials show that stereotactic ablative body radiotherapy (SABR) to oligometastases may delay cancer progression and initiation of androgen deprivation therapy (ADT) and its untoward effects. ADT with radiation prolongs survival in locally advanced PCa and in CIM metastatic PCa. However, there is a knowledge gap about timing and benefit vs toxicity of ADT with SABR in early oligometastatic PCa. NRG GU011 (PROMETHEAN) is a randomized phase II trial of SABR with or without relugolix for early PET-detected recurrent oligometastatic PCa. This study aims to evaluate the impact of relugolix, a novel oral gonadotropin-releasing hormone receptor antagonist, when combined with SABR to oligometastases. Relugolix allows for rapid testosterone recovery and is associated with fewer cardiovascular events when compared to leuprolide and is hypothesized to have low late ADT toxicity. GU011 will provide patients and their physicians data on the relative risks and benefits of early or delayed ADT in this setting. Methods: NRG-GU011 NCT# 05053152 is a randomized phase II double-blinded, placebo-controlled trial with randomization to SABR + 6 months placebo vs SABR + 6 months relugolix. Eligible patients have biochemical recurrence after prior curative intent radiation or surgery for localized PCa, PSA < 10 ng/mL, negative CIM and 1-5 PET-evident metastases (≥1 extrapelvic). SABR is delivered in 1-5 fractions to BED >100 Gy1.5, followed by placebo or relugolix 120mg daily for 6 months. Patients will then be followed with imaging at time of biochemical recurrence. The planned sample size of 260 patients (130 per arm) will provide 85% power to detect a hazard ratio of 0.65 for radiographic progression-free survival (rPFS), based on a one-sided test at alpha 0.10. Planned enrollment is predicted at 8 patients per month with an estimated study completion date of late 2026. The primary endpoint is CIM rPFS. Secondary endpoints include PET-based rPFS, sexual and hormonal quality of life (QoL) assessed by EPIC-26, other QoL measures from EQ5D-5L, EORTC QLQ-30 and PROMIS Fatigue, and between-group comparisons of time to salvage therapy, castration-resistance, local progression (SABR-targeted lesion), biochemical progression, distant metastases, prostate cancer-specific mortality, metastasis-free survival, and overall survival. We also aim to determine adverse event rates for both treatment arms and evaluate genomic and blood markers of treatment response. This study opened in December 2021. Clinical trial information: NCT05053152 .
Abstract P500: Age-Specific Population Attributable Fractions for the Impact of Hypertension on Dementia Risk
Smith, Jason, Sharrett, A R, Lee, Mark , Palta, Priya, Windham, B Gwen, Sharrett, A.R, Pike, James Russell , Gottesman, Rebecca F. , Knopman, David S. , Lutsey, Pamela L. , Windham, B. Gwen , Coresh, Josef , Deal, Jennifer A.

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p500 Get It

Introduction: Hypertension in midlife, but not late life, is a robust predictor of subsequent dementia. However, the fraction of dementia attributable to hypertension might vary depending on the age of the population considered, and the age through which dementia onset occurs. Here, we investigated associations of hypertension assessed at various ages with incident dementia by age 80 or 90, then estimated population attributable fractions (PAF) for dementia from hypertension categories at each of these age groups. Hypothesis: Given hypertension prevalence increases with age but its relative risk for dementia tends to decrease, we had no prior expectation of the age at which the PAF’s would be highest. We hypothesized, however, that PAFs for incident dementia would be higher when hypertension is measured in midlife age groups versus late-life age groups. Methods: We leveraged 32 years of follow-up data from the Atherosclerosis Risk in Communities study (ARIC), a prospective, community-based cohort that enrolled participants aged 45-64 years from four US communities (Washington County, MD; Forsyth County, NC; Jackson, MS; and selected suburbs of Minneapolis, MI) at ARIC visit 1 (1987-1989). Participants were followed through 2018-2019. We used Cox proportional hazards models to estimate hazard ratios, then quantified PAFs, of dementia by age 80 and 90 from hypertension assessed at ages of 45-54 (ARIC visit 1), 55-64 (ARIC visits 1 and 4), 65-74 (ARIC visits 4 and 5), and 75-84 (ARIC visit 5). Results: Hypertension was assessed among 7,572 participants aged 45-54; 12,033 aged 55-64; and 6,561 aged 65-74. By age 80 the number identified as having incident dementia was 711, 910, and 372, respectively. Relative to normotension, hypertension in each age category was associated with hazard ratios (HRs) greater than 1.0 for dementia from hypertension by age 80. The PAF for dementia by age 80 from hypertension measured at age 45-54 was 15.3% (95% CI = 6.9, 22.3%), 19.1% (95% CI = 9.9, 26.9%) at ages 55-64, and 19.9% (95% CI = -4.4, 38.5%) at ages 65-74. By age 90, the number of incident dementia cases were 958; 2,302; and 1,327, respectively; and, among the 2,086 participants aged 75-84, 400 incident dementia cases. HRs were slightly smaller than those by age 80, while hypertension assessed in the 75-84 age group was not significant. The PAFs for dementia by age 90 from hypertension at age 45-54 was 13.8% (95% CI = 6.6, 20.0%), 12.9% (95% CI = 7.0, 18.2%) at ages 55-64, 10.9% (95% CI = 0.02, 21.0%) at ages 65-74, and non-significant at ages 75-84. Conclusions: Public health interventions targeting hypertension in midlife through early late-life might reduce a sizeable proportion of dementia cases.
Abstract P110: Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk
Rich‐Edwards, Janet W. , Stuart, Jennifer , Manson, JoAnn E. , Merz, C. Noel Bairey , Mukamal, Kenneth Jay , Rexrode, Kathryn M. , Shufelt, Chrisandra

Mayo Clinic

Circulation | March 14, 2023 | Volume: 147 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.147.suppl_1.p110 Get It

Introduction: Hypothalamic amenorrhea (HA) is a neuroendocrine disorder characterized by ovulatory dysfunction, anovulation, and infertility, which can be prolonged for months to years. Menstrual cycle irregularity and amenorrhea identify individuals with higher CVD risk, but existing evidence has not examined HA separately from polycystic ovary syndrome (PCOS). It remains unknown whether HA is associated with CVD events across the lifecourse. Hypothesis: We hypothesized that the HA phenotype (oligo/amenorrhea without PCOS traits) would identify individuals at increased risk for CVD. Methods: Nurses’ Health Study II participants with available information on menstrual cycle characteristics who were premenopausal and free of CVD at baseline comprised the analytic sample (n=83,281). Menstrual cycle regularity was retrospectively reported for ages 18-22y on the baseline questionnaire in 1989 while the 1993 biennial questionnaire captured current menstrual cycle regularity (at ages 29-49y); PCOS traits (severe acne, hirsutism) were additionally ascertained in 1993. Participants were followed for confirmed incident CVD (MI, stroke, and fatal CHD) from 1993 through 2017. Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the relationship between HA and CVD, adjusted for age, race/ethnicity, parental education, parental history of CVD <60y, and behavioral risk factors (smoking, physical activity, diet, alcohol intake, body mass index). Results: Thirteen percent of participants (n=11,071) ever had HA: 8.5% of participants (n=7,081) had HA at ages 18-22y while 6.5% (n=5,428) had HA at ages 29-46y. Persistent HA (HA at both 18-22y and 29-46 y) was identified in 1.7% of participants (n=1,438). CVD events occurred in 253 individuals who ever had HA (HA at either 18-22y or 29-46y) and 1,228 individuals without the HA phenotype. Individuals who ever had HA had a 20% higher rate of CVD (CI: 1.05-1.38). HA phenotype at ages 18-22y was not associated with CVD risk (HR=1.14; CI: 0.96-1.35) while HA phenotype at ages 29-46y was associated with a 30% higher rate of CVD (CI: 1.10-1.54) compared to individuals without HA phenotype. Individuals with persistent HA across both age ranges had a 69% higher rate of CVD (CI: 1.24-2.28). Underlying associations were strongest between ever HA and stroke (HR=1.25; CI: 1.03-1.51) and between persistent HA and CHD (HR=1.90; CI: 1.27-2.86), although case counts were small. Conclusions: HA phenotype in mid-adulthood identified individuals at increased risk of CVD compared to those without HA. As there are multiple HA subtypes, defined by varying combinations of psychosocial stress, anxiety, physical activity and weight loss, future studies should examine which HA subtypes are associated with CVD risk.
Integrating Environmental Data with Medical Data in a Records-Linkage System to Explore Groundwater Nitrogen Levels and Child Health Outcomes
Prissel, Christine M. , Klinger, Gregory S., Rocca, Walter A. , Grossardt, Brandon R , Rocca, Walter A , Grossardt, Brandon R. , Sauver, Jennifer L. St.

Mayo Clinic

International Journal of Environmental Research and Public Health | March 14, 2023 | Volume: 20 | Issue: 6 | Pages: 5116

10.3390/ijerph20065116 | PMID 36982025 Get It

Background: The Rochester Epidemiology Project (REP) medical records-linkage system offers a unique opportunity to integrate medical and residency data with existing environmental data, to estimate individual-level exposures. Our primary aim was to provide an archetype of this integration. Our secondary aim was to explore the association between groundwater inorganic nitrogen concentration and adverse child and adolescent health outcomes. Methods: We conducted a nested case-control study in children, aged seven to eighteen, from six counties of southeastern Minnesota. Groundwater inorganic nitrogen concentration data were interpolated, to estimate exposure across our study region. Residency data were then overlaid, to estimate individual-level exposure for our entire study population (n = 29,270). Clinical classification software sets of diagnostic codes were used to determine the presence of 21 clinical conditions. Regression models were adjusted for age, sex, race, and rurality. Results: The analyses support further investigation of associations between nitrogen concentration and chronic obstructive pulmonary disease and bronchiectasis (OR: 2.38, CI: 1.64–3.46) among boys and girls, thyroid disorders (OR: 1.44, CI: 1.05–1.99) and suicide and intentional self-inflicted injury (OR: 1.37, CI: >1.00–1.87) among girls, and attention deficit conduct and disruptive behavior disorders (OR: 1.34, CI: 1.24–1.46) among boys. Conclusions: Investigators with environmental health research questions should leverage the well-enumerated population and residency data in the REP.
Commentary: Gender differences in payments to cardiothoracic surgeons are unacceptable
Jacobs, Jeffrey P. , Nelson, Jennifer S. , Fuller, Stephanie , Karamlou, Tara , Molena, Daniela , Preventza, Ourania , Romano, Jennifer C., Jacobs, Jeffery P , Antonoff, Mara B. , Blackmon, Shanda

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 13, 2023 | Volume: 63 | Issue: 3 | Pages: No page available

10.1093/ejcts/ezad080 | PMID 36912682 Get It

Every effort must be made by the leaders in our field, as well as by every individual cardiothoracic surgeon, to assure equal opportunity for all cardiothoracic surgeons, regardless of race, gender or any other sociodemographic source of bias. Every effort must be made by every surgeon, not just those in particular leadership roles. Opportunities for advancement must be equal in multiple domains, including clinical practice, patient referral, clinical leadership, academic leadership, institutional leadership and leadership in professional medical and surgical societies. Such actions to minimize bias and promote inclusivity will also ensure that cardiothoracic surgical care is provided by a workforce that represents the diversity of patients whom we serve. In the final analysis, it is an absolute fact that gender differences in payments to cardiothoracic surgeons are absolutely unacceptable and cannot be tolerated.
AAPM task group report 275.S: Survey strategy and results on plan review and chart check practices in US and Canada
Harmsen, William S. , Johnson, Jennifer L. , Wells, Michelle, Santos, Luis E. Fong de los, Fong de Los Santos, Luis E, Schofield, Deborah , Conroy, Leigh , Dong, Lei

Mayo Clinic

Journal of Applied Clinical Medical Physics | March 10, 2023 | Volume: 24 | Issue: 4 | Pages: No page available

10.1002/acm2.13952 | PMID 36897824 Get It

AbstractBackgroundAAPM Task Group (TG) 275 was charged with developing practical, evidence‐based recommendations for physics plan and chart review clinical processes for radiation therapy. As part of this charge, and to characterize practices and clinical processes, a survey of the medical physics community was developed and conducted. Detailed analyses and trends based on the survey that exceeded TG report length constraints are presented herein.AimsThe design, development, and detailed results of the TG‐ 275 survey as well as statistical analysis and trends are described in detail. This is complementary material to the TG 275 report.Methods and materialsThe survey consisted of 100 multiple‐choice questions divided into four main sections: 1) Demographics, 2) Initial Plan Check, 3) On‐Treatment, and 4) End‐of‐Treatment Chart Check. The survey was released to all AAPM members who self‐reported working in the radiation oncology field, and it was kept open for 7 weeks. Results were summarized using descriptive statistics. To study practice differences, tests of association were performed using data grouped by four demographic questions: 1) Institution Type, 2) Average number of patients treated daily, 3) Radiation Oncology Electronic Medical Record, and 4) Perceived Culture of Safety.ResultsThe survey captured 1370 non‐duplicate entries from the United States and Canada. Differences across practices were grouped and presented based on Process‐Based and Check‐Specific questions. A risk‐based summary was created to show differences amongst the four demographic questions for checks associated with the highest risk failure modes identified by TG‐275.ConclusionThe TG‐275 survey captured a baseline of practices on initial plan, on‐treatment, and end‐of‐treatment checks across a wide variety of clinics and institutions. The results of test of association showed practice heterogeneities as a function of demographic characteristics. Survey data were successfully used to inform TG‐275 recommendations.
Leveraging expertise and optimizing clinical research: Initial success of a pediatric epilepsy surgery collaborative
Koop, Jennifer I. , Ailion, Alyssa , Bearden, Donald J. , Boyer, Katrina, Cooper, Crystal , Decrow, Amanda M. , Duong, Priscilla, Espe‐Pfeifer, Patricia , Gabriel, Marsha, Hodges, Elise K. , Marshall, David , Molnar, Andrew E. , Olsen, Emily , Ono, Kim E , Patrick, Kristina E. , Paul, Brianna M., Romain, Jonathan, Sepeta, Leigh , Stilp, Rebecca L.H., Wilkening, Greta , Zaccariello, Michael J. , Perry, Μ. Scott , Workgroup, the PERC Surgery, Gaillard, William D. , Eschbach, Krista , McNamara, Nancy , Gedela, Satyanarayana , Javarayee, Pradeep , Armstrong, Dallas , Berl, Madison , Koop, Jennifer I , Ailion, Alyssa , Bearden, Donald J , Cooper, Crystal M , Decrow, Amanda M , Espe-Pfeifer, Patricia , Hodges, Elise , Marshall, David F , Molnar, Andrew E , Olsen, Emily K , Ono, Kim E , Patrick, Kristina E , Sepeta, Leigh N , Zaccariello, Michael, Perry, Michael Scott , Eschbach, Krista , Gaillard, William D , McNamara, Nancy A , Javarayee, Pradeep K , Armstrong, Dallas Michael , Berl, Madison M. , McNally, Kelly A. , Zelko, Frank A. J. , Workgroup, the PERC Surgery

Mayo Clinic

Epilepsia | March 10, 2023 | Volume: 64 | Issue: 6 | Pages: 1554-1567

10.1111/epi.17579 | PMID 36897767 Get It

AbstractObjectiveImprove data‐driven research to inform clinical decision‐making with pediatric epilepsy surgery patients by expanding the Pediatric Epilepsy Research Consortium Epilepsy Surgery (PERC‐Surgery) Workgroup to include neuropsychological data. This article reports on the process and initial success of this effort and characterizes the cognitive functioning of the largest multi‐site pediatric epilepsy surgery cohort in the United States.MethodsPediatric neuropsychologists from 18 institutions completed surveys regarding neuropsychological practice and the impact of involvement in the collaborative. Neuropsychological data were entered through an online database. Descriptive analyses examined the survey responses and cognitive functioning of the cohort. Statistical analyses examined which patients were evaluated and if composite scores differed by domain, demographics, measures used, or epilepsy characteristics.ResultsPositive impact of participation was evident by attendance, survey responses, and the neuropsychological data entry of 534 presurgical epilepsy patients. This cohort, ages 6 months to 21 years, were majority White and non‐Hispanic, and more likely to have private insurance. Mean intelligence quotient (IQ) scores were below to low average, with weaknesses in working memory and processing speed. Full‐scale IQ (FSIQ) was lowest for patients with younger age at seizure onset, daily seizures, and magnetic resonance imaging (MRI) abnormalities.SignificanceWe established a collaborative network and fundamental infrastructure to address questions outlined by the Epilepsy Research Benchmarks. There is a wide range in the age and IQ of patients considered for pediatric epilepsy surgery, yet it appears that social determinants of health impact access to care. Consistent with other national cohorts, this US cohort has a downward shift in IQ associated with seizure severity.